Loxoprofen-containing pharmaceutical composition

A pharmaceutical composition of loxoprofen, glycine, and ethenzamide addresses stability issues in loxoprofen formulations by enhancing storage stability and suppressing appearance changes.

JP2024163040APending Publication Date: 2024-11-21TAISHO PHARMACEUTICAL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024072700
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-04-26
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Loxoprofen formulations experience stability issues such as appearance changes and discoloration due to adhesion to other drugs and containers, and have flavor problems due to bitterness, making formulation development challenging.

Method used

A pharmaceutical composition comprising loxoprofen or its salt, glycine, and ethenzamide, with specific mass ratios and contact conditions, to enhance storage stability and suppress appearance changes.

Benefits of technology

The composition achieves excellent storage stability by minimizing appearance changes and discoloration, maintaining formulation integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163040000001
    Figure 2024163040000001
  • Figure 2024163040000002
    Figure 2024163040000002
  • Figure 2024163040000003
    Figure 2024163040000003
Patent Text Reader

Abstract

To provide a pharmaceutical composition containing loxoprofen or a salt thereof and glycine, exhibiting high storage stability.SOLUTION: The present invention provides a pharmaceutical composition that contains (A) loxoprofen or a salt thereof, (B) glycine, and (C) ethenzamide or a salt thereof, and a method for preventing changes in the appearance of a pharmaceutical composition that contains (A) loxoprofen or a salt thereof and (B) glycine, characterized by blending (C) ethenzamide or a salt thereof into the pharmaceutical composition.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition containing loxoprofen or a salt thereof. [Background technology]

[0002] Loxoprofen sodium hydrate is a type of nonsteroidal anti-inflammatory analgesic (NSAID) and is known to be effective in anti-inflammation, analgesia and antipyresis for rheumatoid arthritis, osteoarthritis, lower back pain, shoulder periarthritis, cervico-omo-brachial syndrome, toothache, acute upper respiratory tract inflammation, and after surgery, trauma and tooth extraction (Non-Patent Document 1).

[0003] While rofecoxib sodium has the excellent medicinal properties described above, it has a strong tendency to adhere to other drugs, equipment, and containers, making it difficult to formulate unless special care is taken in the formulation (Patent Document 1), and it is known that rofecoxib sodium has a bitter or unpleasant taste that is unique to it, posing a flavor issue (Non-Patent Document 2).

[0004] Glycine (also known as aminoacetic acid) is a type of amino acid, and among α-amino acids in which an amino group is directly attached to the carbon (α-carbon) to which a carboxyl group is bonded, it is the only amino acid that does not have D- or L-stereoisomerism and is classified as a non-polar side chain amino acid. Glycine is also classified as a non-essential amino acid that can be produced in the human body, and is known to be involved in various bodily functions, particularly as a component of porphyrin, which is involved in the function of transporting oxygen in the blood, creatine, which is necessary for muscle movement, the antioxidant glutathione, and the purine body of nucleic acid. Furthermore, glycine is an amphoteric compound and has a buffering effect on gastric juice (Non-Patent Document 3).

[0005] Nonsteroidal antipyretic analgesics and anti-inflammatory drugs such as loxoprofen have a pharmacological mechanism of action that inhibits the biosynthesis of prostaglandins, and are therefore known to have the risk of causing a side effect called gastric mucosal damage. On the other hand, it has been reported that gastric mucosal damage caused by loxoprofen can be significantly alleviated by the incorporation of an antacid, and a preparation that combines these is known (Patent Document 2). It has also been reported that the loxoprofen content decreases when loxoprofen is combined with glycine, and that the decrease in content is suppressed by adding potassium dihydrogen phosphate (Patent Document 3). However, there has been no report on the change in appearance when loxoprofen and glycine are simultaneously combined. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 62-242616 [Patent Document 2] JP 2006-52210 A [Patent Document 3] Patent Publication No. 2022-74106 [Non-patent literature]

[0007] [Non-Patent Document 1] Commentary on the 17th revised Japanese Pharmacopoeia Hirokawa Publishing Co., Ltd. No. C-5998~C6002 [Non-Patent Document 2] Abstracts of the Annual Meeting of the Pharmaceutical Society of Japan Vol.121 No.3 Page.132 [Non-Patent Document 3] 18th Edition Japanese Pharmacopoeia Commentary C-1617~C-1620 Summary of the Invention [Problem to be solved by the invention]

[0008] The present inventors have confirmed the stability of a preparation containing both loxoprofen and glycine, and have surprisingly found that changes in appearance (spots and discoloration) occur over time.

[0009] Therefore, an object of the present invention is to provide a pharmaceutical composition which contains loxoprofen or a salt thereof and glycine and has excellent storage stability. [Means for solving the problem]

[0010] The inventors have conducted various investigations to solve the above problems and have found that by incorporating ethenzamide, a pharmaceutical composition containing rofecoxib and glycine can be obtained which has excellent storage stability and suppresses changes in appearance.

[0011] That is, the present invention (1) A pharmaceutical composition comprising (A) loxoprofen or a salt thereof, (B) glycine, and (C) ethenzamide or a salt thereof. (2) The pharmaceutical composition according to claim 1, wherein the content ratio of the component (A) to the component (B) is 1 to 20 parts by mass of the component (B) per 1 part by mass of the component (A). (3) The pharmaceutical composition according to claim 1 or 2, wherein the content of the component (C) is 0.1 to 10 parts by mass per 1 part by mass of the combined amount of the components (A) and (B). (4) The pharmaceutical composition according to claim 1 or 2, which is a solid formulation. (5) A method for suppressing a change in appearance of a pharmaceutical composition containing (A) loxoprofen or a salt thereof, and (B) glycine, the method being characterized in that the pharmaceutical composition further contains (C) ethenzamide or a salt thereof. It is. Effect of the Invention

[0012] According to the present invention, it is possible to provide a pharmaceutical composition containing loxoprofen or a salt thereof and glycine, which has excellent storage stability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The pharmaceutical composition containing loxoprofen or a salt thereof of the present invention will be described in detail below.

[0014] <Component (A)> The (A) loxoprofen or a salt thereof in the pharmaceutical composition of the present invention includes not only loxoprofen but also pharma- ceutically acceptable salts of loxoprofen, and further solvates with water, alcohol, etc. These are known compounds and can be produced by known methods, or commercially available products can be used. In the present invention, the preferred loxoprofen or a salt thereof is loxoprofen sodium hydrate or loxoprofen sodium dihydrate. The salt of rofecoxib in the pharmaceutical composition of the present invention may be any pharma- ceutically acceptable salt, and examples thereof include sodium salt, potassium salt, ammonium salt, meglumine salt, Tris salt, and salts of basic amino acids. The content of rofecoxib or a salt thereof in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, and may be appropriately determined depending on the gender, age, symptoms, etc. of the user. The daily dosage for adults aged 15 years or older is usually 5 to 750 mg, preferably 10 to 500 mg, and more preferably 50 to 250 mg. The content of loxoprofen relative to the total mass of the pharmaceutical composition is preferably 0.01 to 80 mass%, more preferably 0.05 to 60 mass%, further preferably 0.1 to 40 mass%, and particularly preferably 1 to 20 mass%.

[0015] <(B) component> The glycine (B) in the pharmaceutical composition of the present invention is glycine in accordance with the Japanese Pharmacopoeia, and can be produced by known methods, or a commercially available product can be used. The amount of glycine in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, and may be appropriately determined depending on the gender, age, symptoms, etc. of the recipient. The daily dose for an adult aged 15 years or older is usually 5 to 1500 mg, preferably 10 to 1200 mg, and more preferably 60 to 900 mg. Furthermore, the content of glycine relative to the total mass of the pharmaceutical composition is preferably 1 to 90 mass%, more preferably 3 to 80 mass%, further preferably 5 to 70 mass%, and particularly preferably 20 to 40 mass%.

[0016] The total content of the components (A) and (B) contained in the pharmaceutical composition of the present invention is preferably 1 to 90% by mass, more preferably 10 to 70% by mass, and even more preferably 20 to 50% by mass. The content ratio of the components (A) and (B) is not particularly limited, but is preferably 0.01 to 60 parts by mass, more preferably 0.1 to 40 parts by mass, and even more preferably 1 to 20 parts by mass of glycine (B) per part by mass of loxoprofen (A).

[0017] <(C) component> The component (C) of the present invention is ethenzamide or a salt thereof from the viewpoint of suppressing changes in appearance. Other antipyretic and analgesic ingredients such as acetaminophen, ibuprofen, and acetylsalicylic acid do not show any effect of suppressing changes in appearance, and this effect is unique to the ethenzamide of the present invention. Ethenzamide (2-ethoxybenzamide) in the pharmaceutical composition of the present invention is a salicylic acid-based nonsteroidal anti-inflammatory drug (NSAIDs) and is used as an antipyretic and analgesic ingredient. The salt of ethenzamide in the pharmaceutical composition of the present invention may be any pharma- ceutical acceptable salt, and examples thereof include sodium salt, potassium salt, ammonium salt, meglumine salt, tris salt, salt of a basic amino acid, and the like. The content of ethenzamide in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, and may be appropriately determined depending on the gender, age, symptoms, etc. of the recipient. The daily dosage for adults aged 15 years or older is preferably 150 to 1500 mg, more preferably 200 to 1500 mg, and even more preferably 250 to 1500 mg. The content of ethenzamide relative to the total mass of the pharmaceutical composition is preferably 3 to 90 mass%, more preferably 5 to 80 mass%, further preferably 10 to 70 mass%, particularly preferably 30 to 60 mass%, and is preferably 0.1 to 10 mass parts per part by mass of the combined amount of components (A) and (B).

[0018] The pharmaceutical composition of the present invention is not particularly limited as long as it is in a dosage form specified in the General Rules for Preparations of the Japanese Pharmacopoeia, but from the viewpoint of appearance change, it is preferably a tablet, a powder, a fine granule, a granule, a pill, or a capsule, particularly preferably a tablet, a powder, a fine granule, or a granule, and most preferably a tablet. Tablets specified in the General Rules for Preparations of the Japanese Pharmacopoeia include orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, dissolving tablets, film-coated tablets, sugar-coated tablets, and laminated tablets. In addition, the tablets may be provided with a score line, a mark for improving identification, or a stamp. Furthermore, the tablets of the present preparation may be round tablets or irregular tablets. In addition, the present preparation may be a mini tablet.

[0019] When the components (A) and (B) of the present invention are blended so that they are substantially in contact with each other, the degree of change in appearance increases, and when the component (C) is added so that it coexists with these components, the change in appearance can be effectively suppressed. The phrase "component (A), component (B), and component (C) are substantially in contact with each other" refers to a state in which component (A), component (B), and component (C) are mixed together without being physically and / or chemically isolated. However, this does not exclude the blending of components other than component (A), component (B), and component (C), and the coexistence of other components is permitted. In the present invention, even if component (A), component (B), and component (C) are contained in separate granules, this is also included in the state of being substantially in contact with each other, but does not include the case in which component (A), component (B), and component (C) are blended in separate granules and coated so as not to contact each other.

[0020] The pharmaceutical composition of the present invention may contain other commonly used active ingredients, excipients, disintegrants, binders, flow agents, lubricants, acidulants, sweeteners, flavoring agents, refreshing agents, colorants, foaming agents, surfactants, plasticizers, coating agents, and the like, within the qualitative and quantitative ranges that do not impair the effects of the present invention.

[0021] Other active ingredients that can be incorporated into the pharmaceutical composition of the present invention include, for example, antipyretics, antihistamines, antitussives, bronchodilators, expectorants, hypnotics, sedatives, vitamins, amino acids, anti-inflammatory agents, antacids, gastric mucosa protective agents, herbal medicines, Chinese herbal medicine prescriptions, caffeines, and the like, and the pharmaceutical composition may contain one or more kinds selected from the group consisting of these.

[0022] Disintegrants that can be incorporated in the pharmaceutical composition of the present invention include low-substituted hydroxypropyl cellulose, sodium starch glycolate, crospovidone, carmellose, carmellose sodium, carmellose calcium, pregelatinized starch, etc., binders include hydroxypropyl cellulose, hypromellose, gelatin, pregelatinized starch, polyvinylpyrrolidone, pullulan, etc., and lubricants include sucrose fatty acid esters, hardened oils, stearic acid, magnesium stearate, calcium stearate, etc. In the present invention, flavors can be incorporated within the range that does not impair the effects of the present invention.

[0023] The pharmaceutical composition of the present invention can be manufactured by a conventional method, and the method is not particularly limited. Manufacturing method of the tablet of the present invention After mixing the medicamentous active ingredient and the additives as described above in an appropriate mixer such as a mixer to manufacture a mixed powder for tablets, the mixed powder can be directly compressed and tableted, or the granules can be compressed and tableted. The manufacturing method of the granules can be a dry granulation method (slug method, roller compactor method) or a wet granulation method, and is not particularly limited, but is preferably a wet granulation method. As the wet granulation method, it may be manufactured by agitation granulation method, fluidized bed granulation method, extrusion granulation method, rolling granulation method, spray granulation method, etc., and is preferably agitation granulation method or fluidized bed granulation method. As a machine for compressing the mixed powder for tablets or the granules of the mixed powder, a single punch tableting machine, a rotary tableting machine, etc. can be used.

[0024] The packaging form of the pharmaceutical composition of the present invention is not particularly limited, but it can be filled into a commercially available container. From the viewpoint of the quality of the pharmaceutical product, an airtight container or a sealed container is preferable, and an airtight container is more preferable. Examples of the airtight container include glass bottles and plastic packaging. Examples of the plastic packaging include PTP packaging, PTP packaging including aluminum laminate film overlap, strip packaging, SP packaging, plastic bottles, aluminum individual packets (including stick packaging), pouch packaging, etc. EXAMPLES

[0025] The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to these examples.

[0026] (Preparation of solid dosage forms) (Example 1, Comparative Examples 1 to 4, Reference Example 1) Each raw material component of the mixed powder was weighed according to the composition shown in Table 1, and then mixed uniformly to obtain a preparation. (Test Example) <Evaluation method> The mixtures of Example 1, Comparative Examples 1 to 4, and Reference Example 1 were evaluated for storage stability by the following test method. Storage stability (appearance evaluation) The resulting preparations were stored in a sealed state and at 65° C. for 5 days, after which the appearance (presence or absence of spots) was visually observed. Storage stability (color difference) The color difference of the samples stored at 65°C for 5 days was measured using the sample immediately after storage as a control. A spectrophotometer (product name: SE6000; Nippon Denshoku Industries) was used for the measurement, and calculations were made using the following [Equation 1]. The color difference of each sample was measured, and the smaller ΔE*(ab) indicates that the color tone has not changed.

[0027]

number

[0028] ΔL* = L* value of sample stored at 65℃ for 5 days - L* value of sample immediately after storage (L*: lightness + is toward white, - is toward black) Δa* = a* value of sample stored at 65℃ for 5 days - a* value of sample immediately after storage (a*: chromaticity + is toward red, - is toward green) Δb* = b* value of sample stored at 65℃ for 5 days - b* value of sample immediately after storage (b*: chromaticity + is toward yellow, - is toward blue)

[0029] [Table 1]

[0030] As shown in Table 1, spots were observed in Comparative Example 1, but no spots were observed and the color difference was small in Example 1. Spots were observed in all Comparative Examples 2 to 4, and no improvement was observed compared to Comparative Example 1. Furthermore, in Reference Example 1, which contains a blend of loxoprofen and aluminum glycinate, no spots were observed and the color difference was smaller than that of Comparative Example 1. (Examples 2 and 3, Comparative Examples 5 and 6) Each raw material component of the mixed powder was weighed according to the composition shown in Table 2, and then mixed uniformly to obtain a preparation. (Test Example) <Evaluation method> The mixtures of Examples 2 and 3 and Comparative Examples 5 and 6 were evaluated for storage stability by the following test method. Storage stability (appearance evaluation) The resulting preparations were stored in a sealed state and at 65° C. for 5 days, after which the appearance (presence or absence of spots) was visually observed. Storage stability (color difference) The color difference of the samples stored at 65℃ for 5 days was measured using the sample immediately after storage as a control. A spectrophotometer (product name: SE6000; Nippon Denshoku Industries) was used for the measurement, and calculations were made using [Equation 1]. The color difference of each sample was measured, and the smaller ΔE*(ab) indicates that the color tone has not changed.

[0031] [Table 2]

[0032] As shown in Table 2, spots were observed in Comparative Example 5, but no spots were observed and the color difference was small in Example 2. Also, spots were observed in Comparative Example 6, but no spots were observed and the color difference was small in Example 3. [Industrial Applicability]

[0033] According to the present invention, it is possible to provide a pharmaceutical composition which contains loxoprofen or a salt thereof and has excellent storage stability.

Claims

1. A pharmaceutical composition comprising (A) loxoprofen or a salt thereof, (B) glycine, and (C) ethenzamide or a salt thereof.

2. 2. The pharmaceutical composition according to claim 1, wherein the content ratio of the component (A) to the component (B) is 1 to 20 parts by mass of the component (B) per 1 part by mass of the component (A).

3. 3. The pharmaceutical composition according to claim 1, wherein the content of the component (C) is 0.1 to 10 parts by mass per 1 part by mass of the total amount of the components (A) and (B).

4. The pharmaceutical composition according to claim 1 or 2, which is a solid formulation.

5. A method for suppressing changes in appearance of a pharmaceutical composition containing (A) rofecoxib or a salt thereof, and (B) glycine, characterized in that the pharmaceutical composition further contains (C) ethenzamide or a salt thereof.

Citation Information

Patent Citations

  • JP1617C

  • Pharmaceutical preparation containing loxoprofen sodium

    JP1987242616A

  • Loxoprofen-containing oral composition

    JP2006052210A

  • Solid preparation containing loxoprofen and glycine and method for producing the same

    JP2022074106A